1. Home
  2. AER vs BIIB Comparison

AER vs BIIB Comparison

Compare AER & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerCap Holdings N.V.

AER

AerCap Holdings N.V.

HOLD

Current Price

$140.98

Market Cap

24.0B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.54

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AER
BIIB
Founded
1995
1978
Country
Ireland
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
24.2B
IPO Year
2006
1991

Fundamental Metrics

Financial Performance
Metric
AER
BIIB
Price
$140.98
$174.54
Analyst Decision
Strong Buy
Buy
Analyst Count
7
22
Target Price
$146.29
$177.40
AVG Volume (30 Days)
1.5M
2.0M
Earning Date
10-29-2025
10-30-2025
Dividend Yield
0.77%
N/A
EPS Growth
63.90
N/A
EPS
20.89
10.97
Revenue
$8,344,637,000.00
$10,065,900,000.00
Revenue This Year
$4.58
$3.61
Revenue Next Year
N/A
N/A
P/E Ratio
$6.68
$15.86
Revenue Growth
6.67
4.77
52 Week Low
$85.57
$110.04
52 Week High
$142.25
$185.17

Technical Indicators

Market Signals
Indicator
AER
BIIB
Relative Strength Index (RSI) 66.40 55.35
Support Level $131.62 $169.24
Resistance Level $142.25 $180.79
Average True Range (ATR) 2.41 5.03
MACD 0.22 -1.63
Stochastic Oscillator 90.32 36.29

Price Performance

Historical Comparison
AER
BIIB

About AER AerCap Holdings N.V.

AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties.It has one business segment: leasing, financing, sales and management of commercial flight equipment (Commercial Flight Equipment Segment).Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include United Kingdom, United States, and Other countries.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: